Table II.

Subcutaneous growth of transfected or nontransfected B16 melanoma cells in DNA-vaccinated, syngeneic hosts

GroupCells TransferredaTumor Incidencec
Cell lineNo. of cellsMice Immune tob%Tumor-bearing/ transplanted miceCompare groupspd
1B16.F10103HBsAg (S)707/10
2B16.F10104HBsAg (S)10010/10
3B16.F10105HBsAg (S)10010/10
4B16.F10106HBsAg (S)10010/10
5B16.F10/S103HBsAg (S)101/105/10.019*
6B16.F10/S104HBsAg (S)505/106/20.033*
7B16.F10/S105HBsAg (S)606/107/30.087
8B16.F10/S106HBsAg (S)505/108/40.033*
9B16.F10103T-Ag606/10
10B16.F10104T-Ag909/10
11B16.F10105T-Ag10010/10
12B16.F10106T-Ag10010/10
13B16.F10/T103T-Ag00/1013/90.0104*
14B16.F10/T104T-Ag00/1014/100.0001*
15B16.F10/T105T-Ag00/1015/11< 0.0001*
16B16.F10/T106T-Ag404/1016/120.0006*
  • a Nontransfected B16 cells (B16.F10) or B16 cells transfected with HBsAg-encoding BMG/HBS plasmid DNA (B16.F10/S) or T-Ag-encoding vector BMG/T-Ag.1 plasmid DNA (B16.F10/T) were transplanted into C57BL/6 mice; 103, 104, 105, or 106 cells suspended in 0.05 ml PBS were injected s.c. into the left lateral flank.

  • b All mice were injected intramuscularly with 100 μg of plasmid DNA 3 wk before the s.c. tumor cell transplantation. Mice were injected with either pCI/S vector DNA (mice immune to HBsAg or S (small HBsAg)), or pCMV/T vector DNA (mice immune to T-Ag).

  • c Tumor growth was monitored every second or third day. The percentage (%) of mice developing a tumor and the number of tumor-bearing mice/total number of transplanted mice are listed. The data in this table and in Figure 9 are from the same experiment.

  • d p values were calculated using Fisher’s exact test; *, statistically significant.